The clinical immunosuppressant FTY720 is a sphingosine analogue that, once phosphorylated by sphingosine kinase 2 (Sphk2), is an agonist of multiple receptor subtypes for sphingosine 1-phosphate. Short exposures to FTY720 afford long term protection in lymphoproliferative and autoimmune disease models, presumably by inducing apoptosis in subsets of cells essential for pathogenesis. Sphingosine itself is pro-apoptotic, and apoptosis induced with FTY720 or sphingosine is thought to proceed independently of their phosphorylation. Following chemical mutagenesis of Jurkat cells we isolated mutants that are selectively resistant to FTY720 analogue AAL(R), as well as natural sphingolipid bases, including sphingosine. Cells lacking functional Sphk2 were resistant to apoptosis induced with AAL(R), indicating that apoptosis proceeds through AAL(R) phosphorylation. Phosphorylation of AAL(R) was also required for induction of lymphocyte apoptosis in mice, as apoptosis was not induced with the non-phosphorylatable chiral analogue, AAL(S). Apoptosis was induced in the spleen but not the thymus of mice administered 1 mg/kg AAL(R), correlating with levels of AAL(R)-phosphate (AFD(R)) in organ extracts. AFD(R) did not induce apoptosis when added to the cell culture medium, indicating that it induces apoptosis through an intracellular target. NBD-labeled AAL(R) localized to the endoplasmic reticulum, and AAL(R) treatment resulted in elevated cytosolic calcium, Bax redistribution from cytosol to mitochondrial and endoplasmic reticulum membranes, and caspase-independent mitochondrial permeabilization in Jurkat cells. We therefore describe an apoptotic pathway triggered by intracellular accumulation of sphingolipid base phosphates and suggest that sphingoid base substrates for Sphk2 acting intracellularly could be useful in the treatment of lymphoproliferative diseases.The sphingolipids are a class of lipids characterized by a serine head group with one or two fatty acyl tails. The common constituent of all sphingolipids is the long chain base (LCB), 3 and the most commonly occurring LCBs in mammals are sphingosine (Fig. 1A) and dihydrosphingosine. Sphingosine may be phosphorylated by sphingosine kinases 1 and 2 (Sphk1 and Sphk2), yielding sphingosine 1-phosphate (S1P), which has mitogenic and pro-survival properties (1, 2). Ceramides are the N-acylated precursors of sphingosine, generated either through the breakdown of the abundant membrane lipid sphingomyelin, or through de novo synthesis of sphingolipids from palmitoyl coenzyme A and serine. Ceramides have been widely implicated in apoptosis, leading to the proposal of a sphingolipid rheostat, with pro-survival S1P at one end and pro-apoptotic ceramide at the other (1). Sphingosine itself is pro-apoptotic when added exogenously to cells, and its levels are elevated in response to a number of pro-apoptotic stimuli, including antiFas, tumor necrosis factor, and dexamethasone (3, 4). S1P is secreted from cells, following phosphorylation of sphingosine on internal membranes, and may...